Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?

TheMotleyFool 
0 0 23.08.23
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?: https://g.foolcdn.com/editorial/images/744518/female-scientist-observing-with-microscope.jpg
 

By some estimates, the market for nonalcoholic steatohepatitis (NASH) medicines will be worth a startling $108 billion by 2030, even though no drugs are yet on the market for it. That makes it a juicy target for small biotech companies looking to develop the next big drug. It also makes those biotechs potentially lucrative investments, for those who are daring.

But which businesses have the best chance at success in a field where many, including big pharmas, have tried and failed? Let's take a look at three of the myriad of competitors to figure it out.

There is a trio of popular pre-revenue biotechs angling for the NASH market that you may have heard of: Madrigal Pharmaceuticals (NASDAQ: MDGL), Terns Pharmaceuticals (NASDAQ: TERN), and Viking Therapeutics (NASDAQ: VKTX). Terns has a program that's anticipated to enter phase 2b/3 in 2024. Viking's phase 2b trial is already in progress.

Continue reading


Source Fool.com

Viking Therapeutics Inc Stock

€52.42
-7.250%
Viking Therapeutics Inc took a tumble today and lost -€4.100 (-7.250%).

Show more
Like: 0
MDGL
Share

Comments

Not a member yet? Sign up for free!